Enrollment completed in phase 2a study with cocrystal pharma's oral antiviral candidate cc-42344 for pandemic and seasonal influenza

Bothell, wash., may 01, 2024 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces completion of enrollment of 78 subjects who were infected with influenza a in a randomized, double-blind, placebo-controlled phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral pb2 inhibitor cc-42344. cc-42344 is a new class of antiviral treatment designed to effectively block an essential step in the viral replication and transcription of pandemic and seasonal influenza a, and was discovered using the company's proprietary structure-based drug discovery platform technology.
COCP Ratings Summary
COCP Quant Ranking